The Company’s designated products are listed under the FSS category
65IB: Drugs, Pharmaceuticals and Hematology products. The listed
products that are now available for purchase by federal agencies include AppTrim®,
Theramine®, GABAdone®, Sentra AM®
and Sentra PM®.
“Inclusion of our Company’s proprietary medications on the Federal
Supply Schedule provides Military and Veteran healthcare providers
access to effective and safe prescription medications that can greatly
improve patient clinical outcomes without harmful side effects,” said
Dr. William E. Shell, CEO of Targeted Medical Pharma. “The FSS award
provides our Company with the unique opportunity to service the nation’s
federal agencies, providing them with safer, more effective
pharmacologic options for disease management and prevention.”
The FSS listing of the Company’s products became effective with a
contract award by the Department of Veterans Affairs to N3 Technologies,
Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), which is
the contracted distributor to federal agencies for Targeted Medical
Pharma. The FSS contract, V797D-30064, is effective through December 14,
2017.
About Targeted Medical Pharma, Inc.
Targeted
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops prescription medical
foods for the treatment of chronic disease including pain syndromes,
peripheral neuropathy, hypertension, obesity, sleep and cognitive
disorders. The company manufactures ten proprietary prescription-only
medical foods, as well as 48 convenience packed kits, which pair a
medical food and branded or generic pharmaceutical. These prescription
medical foods and therapeutic systems are sold to physicians and
pharmacies in the U.S. and the Middle East through the company’s
division, Physician’s
Therapeutics. These proprietary medications represent a novel
approach to the management of certain disease states, focusing on safety
and efficacy without the deleterious side effects of traditional, high
dose prescription drugs. Targeted Medical Pharma also provides
diagnostic testing as well as billing and collection services on behalf
of dispensing physicians.
Forward-Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma’s business strategy, outlook, objectives, plans,
intentions or goals. The words “believe,” “may,” “will,” “should,”
“plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,”
“project,” “intend,” and similar expressions, identify forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, but their absence does not mean that the statement
is not forward looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaims any obligation
or undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the Company’s expectations
with regard thereto or any change in events, conditions or circumstances
upon which any statement is based.
Business Wire
http://www.businesswire.com/
Last updated on: 07/01/2013 14:00:15